Page last updated: 2024-12-08

migalastat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

migalastat: a potent inhibitor of glycolipid biosynthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID176077
CHEMBL ID110458
CHEBI ID135923
SCHEMBL ID1479364
MeSH IDM0238105

Synonyms (46)

Synonym
gr181413a
nsc658776
tocris-1258
NCGC00025085-01
(2r,3s,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol
2-(hydroxymethyl)-3,4,5-piperidinetriol hydrochloride
d-galactitol, 1,5-dideoxy-1,5-imino
dgj ,
d-galactitol, 1,5-dideoxy-1,5-imino-
1,5-dideoxy-1,5-iminogalactitol
ddig
1-deoxygalactonojirimycin
migalastat
CHEBI:135923
CHEMBL110458 ,
(2r,3s,4r,5s)-2-hydroxymethyl-piperidine-3,4,5-triol
bdbm50163440
d-galacto-1-deoxynojirimycin
unii-c4xny919fw
108147-54-2
1-deoxygalactostatin
c4xny919fw ,
migalastat [usan:inn]
SCHEMBL1479364
migalastat (usan/inn)
D10359
migalastat [who-dd]
migalastat [usan]
migalastat [inn]
migalastat [mi]
3,4,5-piperidinetriol, 2-(hydroxymethyl)-, (2r,3s,4r,5s)-
deoxygalactonojirimycin
A937322
DB05018
1,5-didesoxy-l,5-imino-d-galactitol
gr-181413a
gtpl10200
Q161613
108147-54-2 (free base)
NCGC00686698-01
DTXSID201022520
CS-0003641
HY-14929
EN300-255537
migalastatum
a16ax14

Research Excerpts

Overview

Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations. Migalast at may stabilize the enzyme in specific GLA variants, considered amenable, assisting enzyme trafficking to lysosomes and thus increasing enzyme activity.

ExcerptReferenceRelevance
"Migalastat is an orally-administered small molecule approved to treat the symptoms of Fabry disease in patients with amenable mutations."( Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial.
Barisoni, L; Barth, JA; Bichet, DG; Castelli, JP; Colvin, RB; Feldt-Rasmussen, U; Giugliani, R; Holdbrook, F; Hughes, DA; Jennette, JC; Jovanovic, A; Mulberg, A; Nicholls, K; Schiffmann, R; Shankar, SP; Skuban, N, 2018
)
2.64
"Migalastat is a pharmacological chaperone that may stabilize the enzyme in specific GLA variants, considered amenable, assisting enzyme trafficking to lysosomes and thus increasing enzyme activity."( Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
Gurevich, A; Meiyappan, M; Oommen, S; Qiu, Y; Zhou, Y, 2019
)
1.51
"Migalastat HCl is a candidate oral pharmacological chaperone that provides a potential novel genotype-specific treatment for FD. "( A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Benjamin, ER; Bichet, DG; Boudes, PF; Bragat, AC; Castelli, JP; Germain, DP; Giugliani, R; Nicholls, K; Simosky, JK; Waldek, S, 2013
)
2.16
"Migalastat HCl is an investigational, pharmacological chaperone for mutant α-galactosidase A, which is responsible for Fabry disease, an X-linked, lysosomal storage disorder. "( Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers.
Janmohamed, SG; Johnson, FK; Mudd, PN,
)
1.79

Effects

ExcerptReferenceRelevance
"Oral migalastat has recently been approved for the treatment of Anderson-Fabry disease (FD) in patients aged ≥16 years with amenable mutations on the basis of two phase III trials, FACETS and ATTRACT. "( The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts.
Chimenti, C; Feriozzi, S; Mignani, R; Nencini, P; Pieroni, M; Pieruzzi, F; Pisani, A, 2020
)
1.32

Treatment

Migalastat treatment increased leukocyte alpha-galactosidase A activity, stabilized renal function, and decreased LVMi. Treatment of 6 months duration in eight male patients with Fabry disease demonstrated effective GL3 clearance from the podocyte.

ExcerptReferenceRelevance
"Migalastat treatment increased leukocyte alpha-galactosidase A activity, stabilized renal function, and decreased LVMi."( Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Barth, JA; Castelli, JP; Hamazaki, T; Lagast, H; Narita, I; Ohashi, T; Sakai, N; Skuban, N, 2020
)
1.59
"Migalastat treatment led to a reduction in mean total GL3 inclusion volume per podocyte in renal biopsies from baseline to 6 months. "( Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Barth, JA; Benjamin, ER; Castelli, JP; Mauer, M; Najafian, B; Sokolovskiy, A; Williams, HN, 2017
)
1.9
"Migalastat treatment of 6 months duration in eight male patients with Fabry disease demonstrated effective GL3 clearance from the podocyte, an important and relatively ERT-resistant glomerular cell."( Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
Barth, JA; Benjamin, ER; Castelli, JP; Mauer, M; Najafian, B; Sokolovskiy, A; Williams, HN, 2017
)
1.9
"Treatment with migalastat was generally safe and resulted in most patients in an amelioration of left ventricular mass. "( Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Blaschke, D; Brand, E; Brand, SM; Canaan-Kühl, S; Cybulla, M; Das, AM; Duning, T; Eveslage, M; Gaedeke, J; Hennermann, JB; Kampmann, C; Karabul, N; Kaufeld, J; Kurschat, C; Lenders, M; Liu, D; Mann, WA; Müntze, J; Muschol, N; Nordbeck, P; Patten, M; Pogoda, C; Reiermann, S; Sommer, C; Üçeyler, N; von Cossel, K, 2022
)
1.34

Toxicity

ExcerptReferenceRelevance
" Incidence of adverse events was comparable across all renal function groups."( An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Barlow, C; Boudes, P; DiMino, T; France, N; Johnson, FK; Mudd, PN; Sitaraman, S; Vosk, J, 2015
)
0.65
" Four nonserious adverse events were reported by 4 subjects (1 in group A, 3 in group D)."( Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
Dingemanse, J; Guérard, N; Zwingelstein, C, 2017
)
0.46

Pharmacokinetics

Migalastat and agalsidase beta biodistribution were assessed in mice and modeled using physiologically based pharmacokinetic (PBPK) analysis. Patients with amenable mutations seem to demonstrate greater pharmacodynamic response to migalast at HCl compared to non-amenable mutations.

ExcerptReferenceRelevance
" Patients with amenable mutations seem to demonstrate greater pharmacodynamic response to migalastat HCl compared to patients with non-amenable mutations."( A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
Benjamin, ER; Bichet, DG; Boudes, PF; Bragat, AC; Castelli, JP; Germain, DP; Giugliani, R; Nicholls, K; Simosky, JK; Waldek, S, 2013
)
0.94
" Pharmacokinetic parameters determined were: area under the concentration-time curve (AUC) from time zero to the last measurable concentration postdose (AUC0-t ) and extrapolated to infinity (AUC0-∞ ), maximum observed concentration (Cmax ), time to Cmax (tmax ), concentration at 48 hours postdose (C48h ), terminal elimination half-life (t1/2 ), oral clearance (CL/F), and apparent terminal elimination rate constant (λz) (ClinicalTrials."( An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Barlow, C; Boudes, P; DiMino, T; France, N; Johnson, FK; Mudd, PN; Sitaraman, S; Vosk, J, 2015
)
0.65
" The ratios of LSM (90% CIs) for Cmax were 97."( Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers.
Janmohamed, SG; Johnson, FK; Mudd, PN,
)
0.35
" In pharmacokinetic studies in rats, dogs, and healthy subjects, the main route of elimination was renal."( Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment.
Dingemanse, J; Guérard, N; Zwingelstein, C, 2017
)
0.46
" Here, migalastat and agalsidase beta biodistribution were assessed in mice and modeled using physiologically based pharmacokinetic (PBPK) analysis, and migalastat biodistribution was subsequently extrapolated to humans."( Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice.
Das, AM; Dungan, L; Garcia, A; Hamler, R; Johnson, FK; Khanna, R; Lun, Y; Martin, L; Perry, A; Schiffmann, R; Schmith, V; Shen, JS; Tsai, PC; Wu, YS, 2021
)
2.52
" Optimal sampling theory was used to choose pharmacokinetic sampling times for pediatric studies."( Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment.
Ivaturi, V; Johnson, FK; Leonowens, C; Schmith, V; Wu, YS; Zhou, J, 2022
)
1

Compound-Compound Interactions

ExcerptReferenceRelevance
" Based on preclinical data, migalastat HCl in combination with agalsidase is expected to result in the pharmacokinetic (PK) enhancement of agalsidase in plasma by increasing the systemic exposure of active agalsidase, thereby leading to increased cellular levels in disease-relevant tissues."( Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Adera, M; Barlow, C; Barth, J; Bichet, DG; Boudes, P; Eyskens, F; Flanagan, JJ; Goker-Alpan, O; Holida, M; Johnson, FK; Khanna, R; Lockhart, DJ; Nicholls, K; Shankar, S; Sitaraman, S; Thomas, M; Valenzano, KJ; Warnock, DG; Wustman, BA, 2015
)
1.22

Bioavailability

ExcerptReferenceRelevance
" Lucerastat is an orally bioavailable inhibitor of glucosylceramide synthase (GCS) that is in late stage clinical development for Fabry disease."( Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Garzotti, M; Groenen, PMA; Morand, O; Mühlemann, A; Probst, MR; Rickert, V; Üçeyler, N; Welford, RWD, 2018
)
0.48

Dosage Studied

Migalastat can be used to treat Japanese patients with Fabry disease with GLA mutations amenable to migalastAT according to the dosage and administration approved in other countries. Data from the migAlastat HCl clinical program will guide dosing and intervals.

ExcerptRelevanceReference
" Globotriaosylceramide storage was remarkably reduced in kidney of mice after a 4-week treatment at a dosage of approximately 3 mg/kg body weight/day."( Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease.
Chang, HH; Fan, JQ; Higuchi, Y; Ishii, S; Mannen, K; Shimada, T; Taguchi, A; Yoshioka, H, 2009
)
0.35
" These data suggest that the KD-R and NB-DNJ may be a potential combinatorial therapy for Sandhoff disease by enhancing NB-DNJ delivery to the brain and may allow lower dosing to achieve the same degree of efficacy as high dose monotherapy."( Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Baek, RC; Bronson, RT; Butters, TD; Denny, CA; Heinecke, KA; Kim, YP; Loh, KS; Platt, FM; Seyfried, TN, 2010
)
0.36
" Data from the migalastat HCl clinical program will guide dosing and intervals for patients with Fabry disease with renal impairment."( An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Barlow, C; Boudes, P; DiMino, T; France, N; Johnson, FK; Mudd, PN; Sitaraman, S; Vosk, J, 2015
)
1.01
"Migalastat can be used to treat Japanese patients with Fabry disease with GLA mutations amenable to migalastat according to the dosage and administration approved in other countries."( Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
Barth, JA; Castelli, JP; Hamazaki, T; Lagast, H; Narita, I; Ohashi, T; Sakai, N; Skuban, N, 2020
)
2.31
"05) at lucerastat peak plasma concentration after dosing with 1000 mg (5."( The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
Darpo, B; Dingemanse, J; Mueller, MS; Sidharta, PN; Voors-Pette, C; Xue, H, 2020
)
0.56
" Model-informed drug development optimized dosing and design of clinical studies and supported that no dose adjustments were needed in patients with mild to moderate renal impairment or in adolescent patients ≥45 kg."( Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment.
Ivaturi, V; Johnson, FK; Leonowens, C; Schmith, V; Wu, YS; Zhou, J, 2022
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
glucocerebrosidaseHomo sapiens (human)Potency2.61860.01268.156944.6684AID2101; AID2590; AID2671
alpha-galactosidaseHomo sapiens (human)Potency28.18384.466818.391635.4813AID1467
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.38180.036619.637650.1187AID2100; AID2112; AID2113
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)1.50000.04003.46529.0000AID466668
Alpha-galactosidase AHomo sapiens (human)IC50 (µMol)0.04880.01300.04880.0700AID1435344; AID1435345; AID240937; AID488405
Lysosomal alpha-glucosidaseHomo sapiens (human)IC50 (µMol)6.00000.06002.28897.8000AID466672
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)0.26000.04902.72947.8000AID466667
Glycogen debranching enzymeHomo sapiens (human)IC50 (µMol)10.00008.40009.514310.0000AID466673
Lactase-phlorizin hydrolase Rattus norvegicus (Norway rat)IC50 (µMol)72.00000.12002.98674.4000AID488407
Ceramide glucosyltransferaseHomo sapiens (human)IC50 (µMol)100.00000.09000.13250.2000AID466666
Alpha-galactosidaseCoffea arabica (coffee)IC50 (µMol)0.00300.00300.00300.0030AID488404
Alpha-galactosidaseCoffea arabica (coffee)Ki0.01300.01301.00652.0000AID489426
Non-lysosomal glucosylceramidaseHomo sapiens (human)IC50 (µMol)100.00000.00030.08970.3000AID466671
Alpha-galactosidase CAspergillus nigerIC50 (µMol)1.80001.80001.80001.8000AID241411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (61)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
oligosaccharide metabolic processAlpha-galactosidase AHomo sapiens (human)
negative regulation of nitric oxide biosynthetic processAlpha-galactosidase AHomo sapiens (human)
glycosylceramide catabolic processAlpha-galactosidase AHomo sapiens (human)
glycosphingolipid catabolic processAlpha-galactosidase AHomo sapiens (human)
negative regulation of nitric-oxide synthase activityAlpha-galactosidase AHomo sapiens (human)
glycoside catabolic processAlpha-galactosidase AHomo sapiens (human)
lactose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramide catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
quercetin catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose catabolic processLactase-phlorizin hydrolaseHomo sapiens (human)
maltose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
regulation of the force of heart contractionLysosomal alpha-glucosidaseHomo sapiens (human)
diaphragm contractionLysosomal alpha-glucosidaseHomo sapiens (human)
heart morphogenesisLysosomal alpha-glucosidaseHomo sapiens (human)
glycogen catabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
glucose metabolic processLysosomal alpha-glucosidaseHomo sapiens (human)
lysosome organizationLysosomal alpha-glucosidaseHomo sapiens (human)
locomotory behaviorLysosomal alpha-glucosidaseHomo sapiens (human)
tissue developmentLysosomal alpha-glucosidaseHomo sapiens (human)
aorta developmentLysosomal alpha-glucosidaseHomo sapiens (human)
vacuolar sequesteringLysosomal alpha-glucosidaseHomo sapiens (human)
muscle cell cellular homeostasisLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling postureLysosomal alpha-glucosidaseHomo sapiens (human)
neuromuscular process controlling balanceLysosomal alpha-glucosidaseHomo sapiens (human)
cardiac muscle contractionLysosomal alpha-glucosidaseHomo sapiens (human)
glycophagyLysosomal alpha-glucosidaseHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate metabolic processBeta-galactosidaseHomo sapiens (human)
galactose catabolic processBeta-galactosidaseHomo sapiens (human)
heparan sulfate proteoglycan catabolic processBeta-galactosidaseHomo sapiens (human)
keratan sulfate catabolic processBeta-galactosidaseHomo sapiens (human)
glycosphingolipid catabolic processBeta-galactosidaseHomo sapiens (human)
response to cortisoneBeta-galactosidaseHomo sapiens (human)
response to Thyroglobulin triiodothyronineBeta-galactosidaseHomo sapiens (human)
glycogen biosynthetic processGlycogen debranching enzymeHomo sapiens (human)
glycogen catabolic processGlycogen debranching enzymeHomo sapiens (human)
response to nutrientGlycogen debranching enzymeHomo sapiens (human)
response to glucocorticoidGlycogen debranching enzymeHomo sapiens (human)
protein lipidationCeramide glucosyltransferaseHomo sapiens (human)
glucosylceramide biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
glycosphingolipid biosynthetic processCeramide glucosyltransferaseHomo sapiens (human)
epidermis developmentCeramide glucosyltransferaseHomo sapiens (human)
regulation of signal transductionCeramide glucosyltransferaseHomo sapiens (human)
cell differentiationCeramide glucosyltransferaseHomo sapiens (human)
keratinocyte differentiationCeramide glucosyltransferaseHomo sapiens (human)
leptin-mediated signaling pathwayCeramide glucosyltransferaseHomo sapiens (human)
neuron developmentCeramide glucosyltransferaseHomo sapiens (human)
establishment of skin barrierCeramide glucosyltransferaseHomo sapiens (human)
intestinal lipid absorptionCeramide glucosyltransferaseHomo sapiens (human)
cornified envelope assemblyCeramide glucosyltransferaseHomo sapiens (human)
carbohydrate metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramide catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
cholesterol metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
bile acid metabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycoside catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system neuron developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
lipid glycosylationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of actin filament polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of microtubule polymerizationNon-lysosomal glucosylceramidaseHomo sapiens (human)
glycosphingolipid catabolic processNon-lysosomal glucosylceramidaseHomo sapiens (human)
regulation of membrane lipid distributionNon-lysosomal glucosylceramidaseHomo sapiens (human)
central nervous system developmentNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
catalytic activityAlpha-galactosidase AHomo sapiens (human)
alpha-galactosidase activityAlpha-galactosidase AHomo sapiens (human)
signaling receptor bindingAlpha-galactosidase AHomo sapiens (human)
protein bindingAlpha-galactosidase AHomo sapiens (human)
hydrolase activityAlpha-galactosidase AHomo sapiens (human)
galactoside bindingAlpha-galactosidase AHomo sapiens (human)
protein homodimerization activityAlpha-galactosidase AHomo sapiens (human)
lactase activityLactase-phlorizin hydrolaseHomo sapiens (human)
galactosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glucosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
beta-glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
glycosylceramidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
protein homodimerization activityLactase-phlorizin hydrolaseHomo sapiens (human)
cellobiose glucosidase activityLactase-phlorizin hydrolaseHomo sapiens (human)
phlorizin hydrolase activityLactase-phlorizin hydrolaseHomo sapiens (human)
alpha-1,4-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
carbohydrate bindingLysosomal alpha-glucosidaseHomo sapiens (human)
maltose alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
alpha-glucosidase activityLysosomal alpha-glucosidaseHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
beta-galactosidase activityBeta-galactosidaseHomo sapiens (human)
protein bindingBeta-galactosidaseHomo sapiens (human)
galactoside bindingBeta-galactosidaseHomo sapiens (human)
protein homodimerization activityBeta-galactosidaseHomo sapiens (human)
glycogen debranching enzyme activityGlycogen debranching enzymeHomo sapiens (human)
4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
amylo-alpha-1,6-glucosidase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingGlycogen debranching enzymeHomo sapiens (human)
polysaccharide bindingGlycogen debranching enzymeHomo sapiens (human)
polyubiquitin modification-dependent protein bindingGlycogen debranching enzymeHomo sapiens (human)
beta-maltose 4-alpha-glucanotransferase activityGlycogen debranching enzymeHomo sapiens (human)
protein bindingCeramide glucosyltransferaseHomo sapiens (human)
ceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
dihydroceramide glucosyltransferase activityCeramide glucosyltransferaseHomo sapiens (human)
galactosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosylceramidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
glucosyltransferase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
steryl-beta-glucosidase activityNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular regionAlpha-galactosidase AHomo sapiens (human)
cytoplasmAlpha-galactosidase AHomo sapiens (human)
lysosomeAlpha-galactosidase AHomo sapiens (human)
Golgi apparatusAlpha-galactosidase AHomo sapiens (human)
azurophil granule lumenAlpha-galactosidase AHomo sapiens (human)
lysosomal lumenAlpha-galactosidase AHomo sapiens (human)
extracellular exosomeAlpha-galactosidase AHomo sapiens (human)
cytoplasmAlpha-galactosidase AHomo sapiens (human)
plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
external side of apical plasma membraneLactase-phlorizin hydrolaseHomo sapiens (human)
lysosomeLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal membraneLysosomal alpha-glucosidaseHomo sapiens (human)
plasma membraneLysosomal alpha-glucosidaseHomo sapiens (human)
membraneLysosomal alpha-glucosidaseHomo sapiens (human)
azurophil granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
lysosomal lumenLysosomal alpha-glucosidaseHomo sapiens (human)
intracellular membrane-bounded organelleLysosomal alpha-glucosidaseHomo sapiens (human)
extracellular exosomeLysosomal alpha-glucosidaseHomo sapiens (human)
tertiary granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
ficolin-1-rich granule membraneLysosomal alpha-glucosidaseHomo sapiens (human)
autolysosome lumenLysosomal alpha-glucosidaseHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular regionBeta-galactosidaseHomo sapiens (human)
cytoplasmBeta-galactosidaseHomo sapiens (human)
Golgi apparatusBeta-galactosidaseHomo sapiens (human)
azurophil granule lumenBeta-galactosidaseHomo sapiens (human)
lysosomal lumenBeta-galactosidaseHomo sapiens (human)
intracellular membrane-bounded organelleBeta-galactosidaseHomo sapiens (human)
perinuclear region of cytoplasmBeta-galactosidaseHomo sapiens (human)
extracellular exosomeBeta-galactosidaseHomo sapiens (human)
ficolin-1-rich granule lumenBeta-galactosidaseHomo sapiens (human)
vacuoleBeta-galactosidaseHomo sapiens (human)
extracellular regionGlycogen debranching enzymeHomo sapiens (human)
nucleusGlycogen debranching enzymeHomo sapiens (human)
cytoplasmGlycogen debranching enzymeHomo sapiens (human)
cytosolGlycogen debranching enzymeHomo sapiens (human)
inclusion bodyGlycogen debranching enzymeHomo sapiens (human)
sarcoplasmic reticulumGlycogen debranching enzymeHomo sapiens (human)
secretory granule lumenGlycogen debranching enzymeHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen debranching enzymeHomo sapiens (human)
isoamylase complexGlycogen debranching enzymeHomo sapiens (human)
Golgi membraneCeramide glucosyltransferaseHomo sapiens (human)
membraneCeramide glucosyltransferaseHomo sapiens (human)
Golgi membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
endoplasmic reticulum membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
smooth endoplasmic reticulumNon-lysosomal glucosylceramidaseHomo sapiens (human)
cytosolNon-lysosomal glucosylceramidaseHomo sapiens (human)
plasma membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
membraneNon-lysosomal glucosylceramidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (82)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID489426Inhibition of alpha-galactosidase green coffee beans2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of novel biotin-iminoalditol conjugates.
AID731623Induction of alpha galactosidase A R301Q mutant activity in lymphoblasts derived from Fabry disease patient at 100 uM after 4 days relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID241236Inhibitory concentration against alpha-galactosidase of coffee bean2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID466671Inhibition of GBA2 by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1330605Inhibition of helix decumbens beta-mannosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID488425Inhibition of bovine epididymis alpha-L-fucosidase assessed as p-nitrophenol release at 1000 uM at pH 5.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID488415Inhibition of rice alpha-glucosidase assessed as D-glucose release at 1000 uM at pH 5 after 10 to 30 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID1695063Inhibition of Kluyveromyces lactis beta-galactosidase using o-nitrophenyl-beta-o-D-galactopyranoside as substrate measured for 10 mins2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Arylsulfonyl histamine derivatives as powerful and selective α-glucosidase inhibitors.
AID488404Inhibition of coffee bean alpha-galactosidase assessed as p-nitrophenol release at pH 6.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID1435368Chaperone activity assessed as enhancement of alpha GAL-A N215S mutant enzyme activity in Fabry patient derived lymphocytes up to 50 uM pretreated for 4 days followed by compound washout cultured for 4 days and subsequent 4MU-alpha-galactopyranoside subst2017European journal of medicinal chemistry, Jan-27, Volume: 126Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.
AID489424Inhibition of Agrobacterium sp. beta-glucosidase2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of novel biotin-iminoalditol conjugates.
AID1330595Chaperone activity assessed as enhancement of alpha GAL-A N215S mutant enzyme activity in Fabry patient derived lymphocytes up to 100 uM at pH 4.6 after 4 days using 4MU-alpha-galactopyranoside as a substrate in presence of N-acetylgalactosamine by fluore2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID731138Induction of human beta galactosidase I51T mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1330609Cytotoxicity against human lymphocytes assessed as reduction in cell viability after 48 to 72 hrs by alamar blue assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID488405Inhibition of human lysosome alpha-galactosidase assessed as p-nitrophenol release by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID243726Percent inhibition of beta-galactosidase of bovine liver at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID243650Percent inhibition of human alpha-glucosidase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID466667Inhibition of sucrase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID240937Inhibitory concentration against human alpha-galactosidase2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID488414Inhibition of yeast alpha-glucosidase assessed as p-nitrophenol release at 1000 uM at pH 6.8 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID731627Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 3 mg/kg/day, po administered for 2 weeks measured in spleen relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731135Induction of human beta galactosidase W273L mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731630Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 30 mg/kg/day, po administered for 2 weeks measured in heart relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID243739Percent inhibition of alpha-mannosidase of jack bean tree at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID488423Inhibition of jack bean alpha-mannosidase assessed as p-nitrophenol release at 1000 uM at pH 4.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID1330606Inhibition of human lymphocyte beta-galactosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID488409Inhibition of rat epididymis beta-mannosidase assessed as p-nitrophenol release at 1000 uM at pH 4.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID488412Inhibition of Aspergillus niger amyloglucosidase assessed as p-nitrophenol release at 1000 uM at pH 4.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID466669Inhibition of lactase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID488417Inhibition of almond beta-glucosidase assessed as p-nitrophenol release at 1000 uM at pH 5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID731139Induction of human beta galactosidase R201C mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID243740Percent inhibition of alpha-mannosidase of rat epididymis 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID466668Inhibition of maltase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID243640Percent inhibition of human beta-mannosidase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID731632Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 3 mg/kg/day, po administered for 2 weeks measured in heart relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731137Induction of human beta galactosidase R201H mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1737129Chaperone activity at alpha-GalA R301G mutant in Fabry patient derived fibroblasts assessed as increase in intracellular alpha-GalA activity at 10 uM measured after 5 days by 4-methylumbelliferyl-alpha-D-glucopyranoside substrate based assay relative to c2020European journal of medicinal chemistry, Apr-15, Volume: 192Synthesis of multimeric pyrrolidine iminosugar inhibitors of human β-glucocerebrosidase and α-galactosidase A: First example of a multivalent enzyme activity enhancer for Fabry disease.
AID731628Induction of in human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 30 mg/kg/day, po administered for 2 weeks measured in kidney relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1435344Inhibition of recombinant human alpha GAL-A using 4-methylumbelliferyl alpha-D-galactopyranoside as substrate at pH 4.6 after 15 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.
AID1330604Inhibition of almond beta-glucosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID243727Percent inhibition of beta-mannosidase of rat epididymis at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID240897Inhibitory concentration against human beta-galactosidase2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID243641Percent inhibition of rat intestinal maltase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID240929Inhibitory concentration against beta-galactosidase of rat2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID466666Inhibition of GCS by cell-based assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID488426Inhibition of pig kidney trehalase assessed as p-nitrophenol release at 1000 uM at pH 6.5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID466670Inhibition of GBA1 by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID488402Inhibition of Caldocellum saccharolyticum beta-glucosidase assessed as p-nitrophenol release at pH 5 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID1440004Inhibition of alpha-galactosidase in human PBMC using 4-methylumbelliferyl alpha-D-galactopyranoside as substrate at pH 4.3 after 2 hrs by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
AID243638Percent inhibition of human alpha-fucosidase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID731624Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 30 mg/kg/day, po administered for 2 weeks measured in liver relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1435345Inhibition of recombinant human alpha GAL-A using 4-methylumbelliferyl alpha-D-galactopyranoside as substrate at pH 7 after 15 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.
AID263088Inhibition of Agrobacterium sp. beta-galactosidase2006Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8
Fluorescent glycosidase inhibiting 1,5-dideoxy-1,5-iminoalditols.
AID243664Percent inhibition of alpha-glucosidase of rice 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID243762Percent inhibition of alpha-L-fucosidase of bovine epididymis at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID1435348Chaperone activity assessed as enhancement of alpha GAL-A N215S mutant enzyme activity in Fabry patient derived lymphocytes up to 100 uM at pH 4.6 pretreated for 4 days followed by 4MU-alpha-galactopyranoside substrate addition in presence of N-acetylgala2017European journal of medicinal chemistry, Jan-27, Volume: 126Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.
AID488416Inhibition of rat intestinal maltase assessed as D-glucose release at 1000 uM at pH 5.8 after 10 to 30 mins2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID243651Percent inhibition of human alpha-mannosidase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID489425Inhibition of Escherichia coli beta-galactosidase2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
Synthesis and biological evaluation of novel biotin-iminoalditol conjugates.
AID411656Inhibition of Agrobacterium sp. beta galactosidase2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
1-Deoxygalactonojirimycin-lysine hybrids as potent D-galactosidase inhibitors.
AID731136Induction of human beta galactosidase R457Q mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID488419Inhibition of bovine liver beta-glucosidase assessed as p-nitrophenol release at 1000 uM at pH 6.8 by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID466672Inhibition of lysosomal alpha-glucosidase by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID1330603Inhibition of Bacillus stearothermophilus alpha-glucosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID1330608Inhibition of recombinant human acid alpha-glucosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID466673Inhibition of glycogen glycogen de-branching enzyme by HPLC2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Dual-action lipophilic iminosugar improves glycemic control in obese rodents by reduction of visceral glycosphingolipids and buffering of carbohydrate assimilation.
AID243694Percent inhibition of beta-glucosidase of almond tree at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID241411Inhibitory concentration against alpha-galactosidase of Aspergillus niger2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID731626Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 30 mg/kg/day, po administered for 2 weeks measured in spleen relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731134Induction of human beta galactosidase Y83H mutant activity expressed in beta galactosidase knock out mouse fibroblast at 500 uM relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1435367Cytotoxicity against human lymphocytes measured after 48 to 72 hrs by alamar blue assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Rapid preparation of (3R,4S,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease.
AID488407Inhibition of rat intestinal lactase assessed as p-nitrophenol release by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID488413Inhibition of bovine liver beta-galactosidase assessed as p-nitrophenol release at 1000 uM by spectrometric analysis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
AID1330607Inhibition of recombinant human acid beta-glucosidase at 100 uM using p-nitrophenyl-glycopyranoside or 4-methylumbelliferyl-glycopyranoside as substrate by spectrophotometric method relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
AID243639Percent inhibition of human beta-glucosidase at 1000 uM2005Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
Biological properties of D- and L-1-deoxyazasugars.
AID731625Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 3 mg/kg/day, po administered for 2 weeks measured in liver relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID731629Induction of human alpha galactosidase A R301Q mutant activity expressed in C57BL/6 transgenic alpha galactosidase A knockout mouse at 3 mg/kg/day, po administered for 2 weeks measured in kidney relative to control2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Pharmacological chaperones as therapeutics for lysosomal storage diseases.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1802833β-Gal Inhibitory Assay from Article 10.1074/jbc.M113.529529: \\Structural basis of pharmacological chaperoning for human u00DF-galactosidase.\\2014The Journal of biological chemistry, May-23, Volume: 289, Issue:21
Structural basis of pharmacological chaperoning for human β-galactosidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.43)18.7374
1990's6 (4.29)18.2507
2000's34 (24.29)29.6817
2010's66 (47.14)24.3611
2020's32 (22.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.94 (24.57)
Research Supply Index5.06 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index83.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (9.79%)5.53%
Reviews17 (11.89%)6.00%
Case Studies4 (2.80%)4.05%
Observational2 (1.40%)0.25%
Other106 (74.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]